Pharmacologic IRE1/XBP1s activation confers targeted ER proteostasis reprogramming.

Pharmacologic IRE1/XBP1s activation confers targeted ER proteostasis reprogramming.
复制标题

IRE1/XBP1s的药理激活赋予靶向内质网蛋白稳态重编程。

DOI:
10.1038/s41589-020-0584-z
复制
发表时间:
2020-10
影响因子:
14.8
通讯作者:
Wiseman RL
Wiseman RL
中科院分区:
生物学1区
文献类型:
--
作者:
Grandjean JMD;Madhavan A;Cech L;Seguinot BO;Paxman RJ;Smith E;Scampavia L;Powers ET;Cooley CB;Plate L;Spicer TP;Kelly JW;Wiseman RL

文献摘要

参考文献

被引文献

相似文献

未折叠蛋白反应(UPR)的IRE 1/XBP 1 s信号臂的激活是一种很有前途的策略,以纠正与多种疾病有关的内质网(ER)蛋白质稳态缺陷。然而,迄今为止还没有鉴定出该途径的药理学激活剂通过选择性激活IRE 1/XBP 1 s信号传导而适合于ER蛋白稳态重塑。在这里,我们使用高通量筛选,以确定无毒的化合物,诱导ER蛋白质重构通过IRE 1/XBP 1 s激活。我们采用转录谱来严格确认我们的优先化合物选择性地激活IRE 1/XBP 1 s信号传导,而不激活其他细胞应激反应信号传导途径。此外,我们证明了我们的化合物通过IRE 1依赖性机制改善了淀粉样前体蛋白(APP)不稳定变体的ER蛋白质稳态,并降低了细胞模型中APP相关的线粒体毒性。这些结果建立了高度选择性的IRE 1/XBP 1 s激活化合物,可广泛用于定义IRE 1/XBP 1 s活性在健康和疾病背景下对ER蛋白质稳态调节的功能重要性。
Activation of the IRE1/XBP1s signaling arm of the unfolded protein response (UPR) is a promising strategy to correct defects in endoplasmic reticulum (ER) proteostasis implicated in diverse diseases. However, no pharmacologic activators of this pathway identified to date are suitable for ER proteostasis remodeling through selective activation of IRE1/XBP1s signaling. Here, we use high-throughput screening to identify non-toxic compounds that induce ER proteostasis remodeling through IRE1/XBP1s activation. We employ transcriptional profiling to stringently confirm that our prioritized compounds selectively activate IRE1/XBP1s signaling without activating other cellular stress-responsive signaling pathways. Furthermore, we demonstrate that our compounds improve ER proteostasis of destabilized variants of amyloid precursor protein (APP) through an IRE1-dependent mechanism and reduce APP-associated mitochondrial toxicity in cellular models. These results establish highly selective IRE1/XBP1s activating compounds that can be widely employed to define the functional importance of IRE1/XBP1s activity for ER proteostasis regulation in the context of health and disease.
DOI: 10.7554/elife.05434
发表时间: 2015-05-19
期刊: eLife
影响因子: 7.7
作者:
Mendez AS;Alfaro J;Morales-Soto MA;Dar AC;McCullagh E;Gotthardt K;Li H;Acosta-Alvear D;Sidrauski C;Korennykh AV;Bernales S;Shokat KM;Walter P
通讯作者: Walter P
DOI: 10.1038/ncb2738
发表时间: 2013-05
影响因子: 21.3
作者:
通讯作者: --
DOI: 10.15252/embj.201796797
发表时间: 2017-11-15
期刊: The EMBO journal
影响因子: --
作者:
Pera M;Larrea D;Guardia-Laguarta C;Montesinos J;Velasco KR;Agrawal RR;Xu Y;Chan RB;Di Paolo G;Mehler MF;Perumal GS;Macaluso FP;Freyberg ZZ;Acin-Perez R;Enriquez JA;Schon EA;Area-Gomez E
通讯作者: Area-Gomez E
DOI: 10.1038/nm970
发表时间: 2004-01-01
期刊: NATURE MEDICINE
影响因子: 82.9
作者:
Iwawaki, T;Akai, R;Miura, M
通讯作者: Miura, M
DOI: 10.3233/jad-130728
发表时间: 2013-01-01
影响因子: 4
作者:
Krako, Nina;Magnifico, Maria Chiara;Cattaneo, Antonino
通讯作者: Cattaneo, Antonino